Send this to a friend

Newton biotech firm AesRx LLC has boosted its latest financing round by about $125,000 to $1.5 million, according to a federal document.

AesRx filed in May with the U.S. Securities and Exchange Commission the first tranche of the debt and equities funding for a value of $1.375 million. The top end of the planned round hasn’t changed with the new funding, staying at $3.5 million.

The company, which is focused on treatments for sickle cell disease, has had a busy funding year so far. In March, AesRx was one of a handful of life sciences companies that received $3.75 million in loans from the Massachusetts Life Sciences Center.

AesRx has had its main drug candidate, Aes-103, designated as an orphan drug by the U.S. Food and Drug Administration. The drug was developed for the purpose of lowering the instances of blood cell sickling, a genetic blood defect that causes misshaping of red blood cells.

In November 2010, AesRx announced a collaboration with the National Institutes of Health to bring Aes-103 to clinical trials. The company is also working on the drug candidate Aes-210, currently in a Phase 2 study, which is intended to treat lower intestine inflammatory diseases, such as pouchitis, distal ulcerative colitis and radiation-induced proctitis.

Related links:

Industries:

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.